Australasian Journal of Dermatology provides the latest peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology.

Featured Article

Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting

Peter Foley, Yves A. Kerdraon, John P. Hogden, Stephen Shumack, Lynda Spelman, Deshan Sebaratnam, Charles S. Su, Constance H. Katelaris

Dupilumab-associated ocular surface disease (DAOSD) is of relevance in patients with atopic dermatitis (AD). Guidance on DAOSD assessment and management in the Australian setting is needed to reduce its impact and minimise disruption to treatment. 

A systematic review of the literature was undertaken to understand the epidemiology, pathophysiology, risk factors for DAOSD, and to inform an interdisciplinary decision framework guide the recognition and management of DAOSD .  

The study found that DAOSD usually develops within four months of starting dupilumab, with the occurrence of new cases decreasing over time. The reported incidence of DAOSD varies depending on the nature and source of data, ranging from 8.6% to 22.1% in clinical trials and from 0.5% to 70% in real-world data. Occurrence of DAOSD is more common in patients with severe AD and a history of ocular disease. Pathophysiology is still to be fully understood. Management options include medications such as lubricants/artificial tears, corticosteroids, calcineurin inhibitors, antihistamines, anti-inflammatory agents and antimicrobial agents. Current therapies aim to relieve symptoms or reduce severity to a tolerable level that allows for continued use of dupilumab.   

It was suggested that recommendations for DAOSD include identification of high-risk patients, vigilance for red flags (keratoconus, herpetic and bacterial keratitis), regular assessment of symptom severity and collaborative interdisciplinary management and care, with the aim to reduce the impact of DAOSD and minimise disruption to dupilumab therapy.

About the Journal

The Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society. Editorially independent and peer-reviewed, the journal showcases the latest in dermatology research and innovation.

With four issues a year and special editions, the journal covers clinical presentations, medical and physical therapies and investigations, including dermatopathology, mycology, dermoscopy, surgery and contact dermatitis.

2022 Journal metrics

Accessing the Journal

ACD Members 

ACD members have complimentary access to the AJD. Members can access the journal by logging into the Members only section of College’s website and selecting ‘My Online Journals’. 

Other Readers

Browse contents, abstracts and subscribe here

Free online access to this journal is available within institutions in the developing world through the HINARI initiative with the World Health Organization (WHO). Find out more here.

Editorial Board


Professor Kiarash Khosrotehrani

Institute of Molecular Bioscience, The University of Queensland Diamantina Institute, Brisbane, Australia.

Associate Professor Helmut Schaider

Dermatology Research Centre, School of Medicine, University of Queensland, Brisbane, Australia.

Professor Khosrotehrani is a clinician-scientist, practicing dermatologist with a focus on delivering state of the art concept and technologies to real-world clinical problems.

A Fellow of the Australasian College of Dermatologists (ACD), he leads the Experimental Dermatology Group at the University of Queensland Diamantina Institute in Brisbane, Australia; is deputy director of the Australian Skin and Skin Cancer Research Centre in Brisbane and practises at the Princess Alexandra Hospital and the Skin and Cancer Foundation’s Queensland Institute of Dermatology.

Passionate about the development of academic medicine and future academic clinicians, he is chair of ACD’s Academic Research Committee, President of the Australasian Society for Dermatology Research and a board member of the International Society for Investigative Dermatology.

He obtained his MD in Paris, France specialising in Dermatology and is a former graduate of the Ecole Normale Supérieure and the Institut Pasteur of Paris (Université Paris VI, Pierre et Marie Curie) obtaining a PhD in Physiology and Physiopathology. He completed his post-doctoral training in stem cell biology and clinical genetics at Tufts-New England Medical Centre in Boston, USA.

Acknowledged by the National Health and Medical Research Council (NHMRC) of Australia through an achievement award (2011) and an NHMRC excellence award (2016), his research is fundamentally based on regenerative medicine concepts applied at basic, translational and clinical levels to melanoma, keratinocyte cancers and skin wounds and takes a multidisciplinary approach. This unique expertise and leadership in research is witnessed by a record of highly cited articles (over 3700 citations, H index 33).


Associate Professor Schaider is an academic dermatologist recognised as a clinical researcher in skin cancer focusing on melanoma biology and early detection of melanoma.

He is a Fellow of the Australasian College of Dermatologists, Treasurer of the Australasian Society of Dermatology Research and is practising at the Sunshine Coast University Hospital and the Princess Alexandra Hospital, Brisbane.

He obtained his medical degree at the Medical University of Graz, Austria, and received training as a postdoctoral researcher in pharmacology at the German Cancer Research Centre, Heidelberg, Germany and melanoma biology at The Wistar Institute, Philadelphia, US.

After relocating to Australia, he set up an independent research group at the Translational Research Institute, Brisbane aiming to identify novel targets tackling cancer drug resistance and improving early detection of melanoma. His group recently identified a chronic stress induced drug tolerant phenotype in cancer and found a novel potential druggable target. Early detection of melanoma is utilizing cutting edge technology like 3D whole body photography to develop surveillance programs for high-risk patients.

Dr Nikki Adler Monash University, Melbourne, Australia
Dr Keng Chen Sable Dermatology, Sydney, Australia
Dr Peggy Chen Taranaki District Health Board, New Plymouth, New Zealand
Dr Harriet Cheng Auckland City Hospital, Auckland
Dr Karen Cheung The Skin Hospital, Sydney, Australia
Dr Haady Fallah Concord Repatriation General Hospital, Sydney, Australia
Dr Esther Hong Royal North Shore Hospital of Sydney, Sydney, Australia
Dr Joseph Konya The Skin Hospital, Sydney, Australia
Prof Prasad Kumarasinghe Fiona Stanley Hospital, Perth, Australia
A/Prof Christopher McCormack Peter MacCallum Cancer Centre, Melbourne Australia
Dr Anne O’Neill The Children’s Hospital at Westmead, Sydney Australia
Dr David Orchard Private Suites Royal Children’s Hospital, Melbourne, Australia
Dr Yan Pan Victorian Melanoma Service, Alfred Hospital, VIC, Australia
A/Prof Helmut Schaider Dermatology Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia
A/Prof Stephen Shumack Royal North Shore Hospital of Sydney, Sydney, Australia
Prof Rodney Sinclair University of Melbourne and Epworth Hospital, Melbourne, Australia
Prof H Peter Soyer Dermatology Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia
Dr Keng-Ee Thai Royal Australian Army Medical Corps
Dr Orli Wargon Sydney Children’s Hospital, Sydney, Australia
Dr Ashfaq Marghoob Memorial Sloan Kettering Skin Cancer Center, New York, NY, USA
Prof John McGrath St John’s Institute of Dermatology, London, United Kingdom
Dr Masaru Tanaka Tokyo Woman’s Medical University, Medical Center East, Tokyo, Japan
Dr Mark Tang National Skin Centre, Singapore
Dr Clark C Otley Mayo Clinic, Rochester, USA

Permissions and Questions

If you would like to reproduce material or have further questions relating to the Australasian Journal of Dermatology visit the Journal at  Wiley Online Library or email AJD@wiley.com
Follow the Australasian Journal of Dermatology at Wiley in Research